Metastatic Colorectal Cancers Recruiting Phase 2 Trials for Nivolumab (DB09035)

Also known as: Colorectal cancer metastatic / Metastatic Colorectal Cancer

IndicationStatusPhase
DBCOND0063579 (Metastatic Colorectal Cancers)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03388190METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatinTreatment
NCT03647839Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal CancerTreatment
NCT03800602Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal CancerTreatment
NCT03785210Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic CancersTreatment
NCT03867799iSCORE: Immunotherapy Sequencing in COlon and REctal CancerTreatment
NCT03547999A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRCTreatment
NCT03832621NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerTreatment